Printer Friendly

ALAMAR BIOSCIENCES REPORTS SECOND QUARTER RESULTS

 SACRAMENTO, Calif., April 28 /PRNewswire/ -- Alamar Biosciences Inc. (NASDAQ: ALMR), a research and development company specializing in the development, manufacturing and marketing of in vitro diagnostic testing products, today reported financial results for the second quarter ended March 31, 1993.
 Revenues were $84,200, an increase over revenues of $2,800 for the second quarter in 1992. A major portion of the increase was attributable to a research contract with Pfizer Inc to develop a test kit for antifungal susceptibility, which accounted for more than 50 percent of revenues for the quarter. Sales of susceptibility test kits and alamarBlue(TM), an indicator dye, also increased for the quarter. Alamar reported a net loss for the second quarter of $884,200, or 30 cents per share, compared to a net loss of $818,300, or 37 cents per share, for the same period a year ago.
 For the six months ended March 31, 1993, Alamar reported revenues of $130,700, compared to revenues of $6,400 for the six months ended in March 1992. The company reported a net loss of $1,658,800, or 58 cents per share, for the six months, compared to a net loss of $1,569,300, or 70 cents per share, for the comparative period a year ago.
 Mark Santor, chief financial officer, said a major highlight of the second quarter was the formation of the company's sales and marketing team. "Our sales and marketing team is comprised of top industry people with extensive experience in microbiology marketing and exceptional prior sales records. We refer to them as our 'dream team'," Santor said. He expects the sales force to significantly boost sales revenue over the coming months. "The six account managers have geographic regions to enable us to adequately cover the entire United States," Santor said.
 Looking ahead, the company is awaiting U.S. Food and Drug Administration clearance on two products that, once cleared, will complete Alamar's initial product portfolio of bacteria identification and antibiotic susceptibility testing products. The products, a bacteria identification test kit and a semi-automated reading instrument, are expected to receive FDA clearance in the near future. "With these products cleared, we will be able to collectively address an approximately $530 million worldwide market," Santor said. The company also continues to pursue distribution agreements that will enable it to market its products internationally.
 At March 31, 1993, total assets were $2,969,800. Stockholders' equity was $2,531,500, with 2,965,996 weighted average common shares outstanding for the quarter.
 During the second quarter ended March 31, 1993, the company's units separated into common stock and warrants. Traded on NASDAQ, common stock is found under the symbol ALMR and warrants under the symbol ALMRW.
 Formed in 1988, Alamar Biosciences Inc. develops, manufactures and markets in vitro (outside the body) diagnostic testing products for hospitals, reference laboratories and other health care providers. Alamar's test kits determine which antibiotic and what dosage is effective in treating bacterial infections. The company also markets alamarBlue(TM), an indicator dye for determining cell viability in research and biotechnology applications.
 For information on Alamar Biosciences Inc. via FAX, dial 800-PRO-INFO, extension 141.
 -0- 4/28/93
 /CONTACT: Kenneth Miller, chief executive officer of Alamar Biosciences, 916-567-3475; or Elizabeth Truax, 415-986-1591, or Kathy Brunson, 312-266-7800, both of the Financial Relations Board, for Alamar/
 (ALMR)


CO: Alamar Biosciences Inc. ST: California IN: MTC SU: ERN

SG -- SF006 -- 1805 04/28/93 09:05 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 28, 1993
Words:576
Previous Article:CELL GENESYS REPORTS FIRST QUARTER RESULTS
Next Article:ACUSON REPORTS FIRST QUARTER 1993 RESULTS
Topics:


Related Articles
ALAMAR BIOSCIENCES REPORTS FIRST QUARTER EARNINGS
ALAMAR BIOSCIENCES RAISES OVER $3.1 MILLION THROUGH PRIVATE FINANCINGS
ALAMAR BIOSCIENCES REPORTS FISCAL 1993 RESULTS
ALAMAR BIOSCIENCES REPORTS SECOND QUARTER RESULTS; REVENUES INCREASE NEARLY FIVE-FOLD
ALAMAR BIOSCIENCES REPORTS FISCAL 1994 RESULTS
ALAMAR ANNOUNCES TRIAL DATE IN TRADE SECRET CASE; DIFCO WILL NOT MARKET PRODUCTS BASED ON PATENT IN NEAR FUTURE
ALAMAR BIOSCIENCES, INC. REPORTS FINANCIAL RESULTS FOR FISCAL 1995
AccuMed International Achieves Record Results for the Third Quarter Ended September 30, 1996
AccuMed International Reports Fourth-Quarter and Year-End Results
Bruker BioSciences.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters